NeuroBo Pharmaceuticals (NRBO)
US Market

NeuroBo Pharmaceuticals (NRBO) Stock Price & Analysis


NRBO Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.48 - $63.85
Previous Close$0.48
Average Volume (3M)398.64K
Market Cap
Enterprise Value-$17.64M
Total Cash (Recent Filing)$30.80M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)>-0.1
Aug 15, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.47
Shares Outstanding27,241,685
10 Day Avg. Volume193,748
30 Day Avg. Volume398,636
Standard Deviation0.28
Financial Highlights & Ratios
Price to Book (P/B)1.41
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda1.55
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0



Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Insights

Sorry, No Data Available
There is no website visitor data available for this stock.



What was NeuroBo Pharmaceuticals’s price range in the past 12 months?
NeuroBo Pharmaceuticals lowest stock price was $0.47 and its highest was $63.85 in the past 12 months.
    What is NeuroBo Pharmaceuticals’s market cap?
    Currently, no data Available
    When is NeuroBo Pharmaceuticals’s upcoming earnings report date?
    NeuroBo Pharmaceuticals’s upcoming earnings report date is Aug 15, 2023 which is in 67 days.
      How were NeuroBo Pharmaceuticals’s earnings last quarter?
      NeuroBo Pharmaceuticals released its earnings results on May 24, 2023. The company reported -$0.06 earnings per share for the quarter, the consensus estimate of -$0.06 by $0.
        Is NeuroBo Pharmaceuticals overvalued?
        According to Wall Street analysts NeuroBo Pharmaceuticals’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does NeuroBo Pharmaceuticals pay dividends?
          NeuroBo Pharmaceuticals does not currently pay dividends.
          What is NeuroBo Pharmaceuticals’s EPS estimate?
          NeuroBo Pharmaceuticals’s EPS estimate is -$0.13.
            How many shares outstanding does NeuroBo Pharmaceuticals have?
            NeuroBo Pharmaceuticals has 27,241,686 shares outstanding.
              What happened to NeuroBo Pharmaceuticals’s price movement after its last earnings report?
              NeuroBo Pharmaceuticals reported an EPS of -$0.06 in its last earnings report, expectations of -$0.06. Following the earnings report the stock price went down -4.918%.
                Which hedge fund is a major shareholder of NeuroBo Pharmaceuticals?
                Currently, no hedge funds are holding shares in NRBO


                NeuroBo Pharmaceuticals Stock Smart Score

                This stock does not have enough of the key information we need to rate it accurately. Smart Score is calculated for stocks traded in Nasdaq, NYSE, TSE and LSE with a market cap above $30M and average 3 months trading volume above $30K.
                Learn more about TipRanks Smart Score

                Company Description

                NeuroBo Pharmaceuticals

                NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat neurodegenerative disorders. The company was founded on October 30, 2014 and is headquartered in Boston, MA.


                Top 5 ETFs holding NRBO

                Currently, no data available
                Please return soon. This page is being updated.
                Up to five ETFs with an Outperform Smart Score that hold NRBO. The ETFs are listed according to market value of NRBO within the ETF


                Forecast EPS vs Actual EPS

                Similar Stocks
                Price & Change
                Aptose Biosciences
                ADMA Biologics
                Cellectar Biosciences

                Popular Stocks

                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis